Results 41 to 50 of about 15,854 (193)

Pemphigus scoring systems and their validation studies – A review of the literature

open access: yesDermatologica Sinica, 2023
Pemphigus is a rare autoimmune blistering disease that affects the skin and mucous membranes. Despite recent advances in treatment, pemphigus is associated with high patient mortality and has a significantly negative impact on patients' quality of life ...
Darby Boucher   +2 more
doaj   +1 more source

Lichenoid and Granulomatous Stomatitis: Three Additional Cases and Detailed Immunohistochemical Analysis

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Lichenoid and granulomatous stomatitis (LGS) is a rare condition, with clinicopathological features resembling lichenoid and granulomatous dermatitis. Despite increasing reports, its etiology remains unclear and detailed immunohistochemical (IHC) studies are lacking.
Mariana Paravani Palaçon   +12 more
wiley   +1 more source

Development of a Desmocollin-3 Active Mouse Model Recapitulating Human Atypical Pemphigus

open access: yesFrontiers in Immunology, 2019
Pemphigus vulgaris (PV) is a life-threatening mucocutaneous autoimmune blistering disease. It is often associated with autoantibodies to the desmosomal adhesion proteins Desmoglein 3 (DSG3) and Desmoglein 1 (DSG1).
Roberta Lotti   +6 more
doaj   +1 more source

Utility of IgG4 immunohistochemistry detection in pemphigus diagnosis

open access: yesSAGE Open Medical Case Reports, 2022
Pemphigus includes a group of blistering autoimmune diseases that affect the skin and mucosa, characterized by the formation of epidermal bullous and the presence of antibodies against binding proteins.
Maricela García-Lechuga   +4 more
doaj   +1 more source

Cyclophosphamide is associated with long‐term treatment‐free remission in patients with pemphigus

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objective Pemphigus treatment has seen significant advancements, yet long‐term remission remains a challenge. Comparative data on the long‐term effectiveness of available therapies are limited. We compared 10‐year relapse rates in pemphigus patients treated with azathioprine or cyclophosphamide plus high‐dose IV corticosteroids ...
Bettina Santler   +5 more
wiley   +1 more source

Two Entities, One Patient

open access: yes
JEADV Clinical Practice, EarlyView.
Wael Zaina   +4 more
wiley   +1 more source

Management of Non‐Plaque‐Induced Gingival Conditions: A Systematic Review—Part 2: Inflammatory and Immune Conditions; Neoplasms; and Gingival Pigmentation

open access: yesJournal of Clinical Periodontology, EarlyView.
ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra   +5 more
wiley   +1 more source

Pemphigus and pemphigoid are associated with Alzheimer’s disease in older adults: evidence from the US Nationwide inpatient sample 2016–2018

open access: yesBMC Geriatrics, 2023
Background Pemphigus and pemphigoid are rare autoimmune skin disorders caused by autoantibodies against structural proteins and characterized by blistering of the skin and/or mucous membranes.
Zhen Xie   +5 more
doaj   +1 more source

Onychogryposis Secondary to Underlying Phalangeal Non‐Union

open access: yes
JEADV Clinical Practice, EarlyView.
Sunil Jaiswal   +5 more
wiley   +1 more source

Incidence of P200 pemphigoid: A nationwide study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The anti‐LAMB4 cell‐based immunoassay is a new serological technique that is far superior to dermal immunoblotting for detecting autoantibodies directed against the P200 protein. This method allows a re‐evaluation of the incidence of P200 pemphigoid, which appears to be considerably more frequent than epidermolysis bullosa acquisita.
Fabienne Jouen   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy